SCHEMBL363342

SCHEMBL363342

O=[C]c1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.67
NPC1 O15118 6/20 0.65
RAB9A P51151 6/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
POLB P06746 2/20 0.65
SIRT1 Q96EB6 1/20 0.65
KDM4E B2RXH2 1/20 0.65
MAPT P10636 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CACNA1B Q00975 1/20 0.61
APBA1 Q02410 1/20 0.61
PRMT1 Q99873 1/20 0.59
FFAR1 O14842 1/20 0.59
PGR P06401 1/20 0.59
JAK2 O60674 1/20 0.58
TYK2 P29597 1/20 0.58
F2 P00734 1/20 0.56
PLG P00747 1/20 0.56
PLAU P00749 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL363881 0.93 PTPN1 (0.67) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL126415 0.86 PTPN1 (0.87) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL18103163 0.84 NPC1 (0.88) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL14715824 0.84 NPC1 (0.88) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL11596555 0.84 KCNK3 (0.59) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL14072817 0.84 PTPN1 (0.65) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL1344198 0.84 F2 (0.72) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL27289941 0.82 NPC1 (0.61) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL1535148 0.82 NPC1 (0.50) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL26953087 0.82 PTPN1 (0.88) PTPN1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2417144-B1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE GLYCOM AS (DK) 2017-08-23 EP disclosed
EP-2417143-B1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE GLYCOM AS (DK) 2016-12-21 EP disclosed
US-20160024129-A1 SYNTHESIS OF NEW SIALOOLIGOSACCHARIDE DERIVATIVES GLYCOM A/S (DK) 2016-01-28 US disclosed
US-9187513-B2 N-substituted mannosamine derivatives, process for their preparation and their use GLYCOM A/S (DK) 2015-11-17 US disclosed
US-9102966-B2 Synthesis of sialooligosaccharide derivatives GLYCOM A/S (DK) 2015-08-11 US disclosed
US-9012625-B2 Method for the synthesis of a trisaccharide GLYCOM A/S (DK) 2015-04-21 US disclosed
US-8927698-B2 Method for the synthesis of a trisaccharide GLYCOM A/S (DK) 2015-01-06 US disclosed
US-20140349347-A1 SYNTHESIS OF N-ACETYL-D-NEURAMINIC ACID GLYCOM A/S (DK) 2014-11-27 US disclosed
EP-2791349-A1 SYNTHESIS OF N-ACETYL-D-NEURAMINIC ACID Glycom A/S (DK) 2014-10-22 EP disclosed
WO-2014135167-A1 PURIFICATION OF OLIGOSACCAHARIDES BY REVERSIBLE DERIVATIZATION GLYCOM A/S (DK) 2014-09-12 WO disclosed
EP-2417144-A1 SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE Glycom A/S (DK) 2012-02-15 EP disclosed
EP-2417143-A1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE Glycom A/S (DK) 2012-02-15 EP disclosed
WO-2012007588-A1 SYNTHESIS OF NEW SIALOOLIGOSACCHARIDE DERIVATIVES GLYCOM A/S (DK) 2012-01-19 WO disclosed
WO-2012007585-A1 DERIVATIZATION OF OLIGOSACCHARIDES GLYCOM A/S (DK) 2012-01-19 WO disclosed
WO-2010115935-A1 SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE GLYCOM A/S (DK) 2010-10-14 WO disclosed
WO-2010115934-A1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE GLYCOM A/S (DK) 2010-10-14 WO disclosed
WO-2003028762-A1 NOVEL ANTIMICROBIAL RESISTANCE BLOCKING COMPOSITIONS ETHICON, INC. (US) 2003-04-10 WO disclosed
US-4933355-A ALDOSE REDUCTASE INHIBITORS SANKYO COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed
US-3931142-A Heterocyclic containing disazo compounds CIBA-GEIGY AG (CH) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024129-A1 SYNTHESIS OF NEW SIALOOLIGOSACCHARIDE DERIVATIVES FUCA1, FUT5, FUCA2 PTPN1 3558/4885NPC1 2003/4885RAB9A 823/4885
US-20140349347-A1 SYNTHESIS OF N-ACETYL-D-NEURAMINIC ACID NAPRT, NAMPT, NANS PTPN1 4106/4885NPC1 742/4885RAB9A 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.